<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25588353</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2015</Year>
<Month>02</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1877-718X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>5</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2015</Year>
</PubDate>
</JournalIssue>
<Title>Journal of Parkinson's disease</Title>
<ISOAbbreviation>J Parkinsons Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.</ArticleTitle>
<Pagination>
<MedlinePgn>165-74</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3233/JPD-140456</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Levodopa-carbidopa intestinal gel (LCIG) is delivered continuously via intrajejunal percutaneous gastrostomy tube.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine long-term safety, efficacy and quality of life of LCIG in an open-label extension study.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Patients received 52 weeks of open-label LCIG treatment following a 12-week double-blind, double-dummy trial in which they were randomized to either LCIG or immediate-release oral levodopa-carbidopa. Patient cohort designation was by receipt of LCIG in the preceding trial randomization (continuing-LCIG vs. LCIG-naïve patients).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-two of 66 subjects in the double-blind proceeded to the open-label extension. Most subjects (95%) reported ≥1 adverse event (AE); only 3 subjects (4.8%) discontinued due to AEs. AE incidence declined gradually over 52 weeks. Serious AEs were reported by 23%. LCIG-naïve patients (N = 29) showed a decrease in "Off" time and an increase in "On" time without troublesome dyskinesia (change from baseline to final visit in mean [SD] hours = -2.34 [2.78] P &lt; 0.001 and 2.19 [3.70] P = 0.005, respectively), while continuing-LCIG patients (N = 33) showed sustained "Off" time duration and further improvement in "On" time without troublesome dyskinesia (-0.42 [2.67] P = 0.377 and 1.00 [2.58] P = 0.036, respectively). The majority of patients in both groups (LCIG-naïve, continuing-LCIG, respectively) were rated 'Much Improved' or 'Very Much Improved' at final visit on the Clinical Global Impression-Improvement scale (69.0%, 69.7%).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Continuing-LCIG patients continued to derive benefit from LCIG while the magnitude of improvement among LCIG-naïve patients was similar to that observed for patients on LCIG in the preceding double-blind study. The overall AE profile was consistent with previous phase 3 clinical trials involving the LCIG system.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Slevin</LastName>
<ForeName>John T</ForeName>
<Initials>JT</Initials>
<AffiliationInfo>
<Affiliation>University of Kentucky Medical Center, Lexington, KY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fernandez</LastName>
<ForeName>Hubert H</ForeName>
<Initials>HH</Initials>
<AffiliationInfo>
<Affiliation>Cleveland Clinic, Cleveland, OH, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zadikoff</LastName>
<ForeName>Cindy</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hall</LastName>
<ForeName>Coleen</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Eaton</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dubow</LastName>
<ForeName>Jordan</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chatamra</LastName>
<ForeName>Krai</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Benesh</LastName>
<ForeName>Janet</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>AbbVie Inc., North Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>J Parkinsons Dis</MedlineTA>
<NlmUniqueID>101567362</NlmUniqueID>
<ISSNLinking>1877-7171</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005782">Gels</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>MNX7R8C5VO</RegistryNumber>
<NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002230">Carbidopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016503">Drug Delivery Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005782">Gels</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Parkinson's disease</Keyword>
<Keyword MajorTopicYN="N">clinical trial</Keyword>
<Keyword MajorTopicYN="N">levodopa-carbidopa intestinal gel</Keyword>
<Keyword MajorTopicYN="N">motor fluctuations</Keyword>
<Keyword MajorTopicYN="N">percutaneous endoscopic gastrostomy</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>1</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>1</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>11</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">25588353</ArticleId>
<ArticleId IdType="pii">04427R3701341251</ArticleId>
<ArticleId IdType="doi">10.3233/JPD-140456</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>